Amarin (AMRN) risk factors

73 risks, 10 new, 6 dropped, 17 reworded since the prior year. Amarin relies heavily on its European partnership with Recordati for commercializing VAZKEPA across 59 countries.

69 risks. Amarin relies almost entirely on commercializing VASCEPA and VAZKEPA in the U.S. and Europe. Generic competition and ANDA litigation rulings have severely impacted U.S. revenues. International expansion faces stringent price controls, reimbursement hurdles, and reliance on third-party partners.